TRVI
Trevi Therapeutics, Inc.Company with tickers: TRVI
CIK
1563880
CUSIP
89532M101
Shares Outstanding
141,979,708
Price History
Institutional Holders
Short Volume
Short Interest
Fails to Deliver
Financials
SEC Filings
Earnings Calls
Insider Trades
Congressional Trades
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $14,912,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Research & Development | $9,941,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Operating Income | $-14,912,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| Net Income | $-13,192,000 | USD | 2026-03-31 | 10-Q | 2026-05-05 |
| EPS (Basic) | $-0.09 | USD/shares | 2026-03-31 | 10-Q | 2026-05-05 |
| EPS (Diluted) | $-0.09 | USD/shares | 2026-03-31 | 10-Q | 2026-05-05 |